AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|
24.1 C
New York
Tuesday, September 1, 2026

Tag: produce

newssourceFORcompanyinformationcontent1releasesmarket

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Marler Clark Urges Parents to Stop Using Nara Organics Whole Milk Organic Powdered Infant Formula Amid Multistate Infant Botulism Outbreak — Product Sold Nationwide...

FDA, CDC, and public health officials in California, Pennsylvania, and Washington are investigating; food safety attorney Bill Marler calls it the second formula-linked infant...

There Are 16 Minerals America Produces None Of. The Government Now Calls That a National Security Threat.

A former Pentagon advisor on what Washington is doing about it and where he's looking on U.S. soil. 
A former Pentagon advisor on what Washington is doing about it and where he's looking on U.S. soil.

Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.

Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.

Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US

NEW YORK, June 12, 2026 /PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the...

SpaceX IPO Project Unlimited (Weiss Ratings’ Michael Robinson Disruptors & Dominators Newsletter) Elon’s Trillion Dollar Plan to Save AI

SPCX IPO live: Weiss Ratings' Disruptors & Dominators covers orbital AI supply chain research. 4 bonus reports. Weiss Ratings LLC.

Eight Saints Launches Firm Intentions, a Clean Anti-Aging Neck Cream, Targeting Skincare’s Most Overlooked Area

A targeted clean formula designed to firm, smooth, and hydrate the delicate neck and décolletage, where signs of aging show first. 
A targeted clean formula designed to firm, smooth, and hydrate the delicate neck and décolletage, where signs of aging show first.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProduce

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers